TOLREMO therapeutics AG
Development of resistance-breaking cancer therapies
TOLREMO therapeutics' mission is to prevent non-genetic cancer drug resistance by dismantling the earliest defense to targeted therapies. Led by phenotypic insights, we discovered a pivotal mechanism that governs critical transcriptional resistance pathways. Our clinical compound TT125-802 is an orally available small molecule inhibitor designed to block these survival techniques to significantly improve the response rates and durability of established treatments.
Only registered users have access to funding information.
Please log in or register to continue. Registration is free.
02.09.2025
Regulatory milestones and clinical progress for Swiss biotechs (startupticker.ch)
30.05.2025
Schweizer Biotech-Startups dominieren europäischen Award (startupticker.ch)
06.05.2024
Innosuisse funded 45 Start-up innovation projects (startupticker.ch)
28.03.2024
New additions to startups’ board of directors (startupticker.ch)
Last Tweets
No Jobs
Videos
Swiss Innovation Challenge 2019 (Wirtschaftskammer Baselland)
SCSN 2019
Interview with Stefanie Flückiger-Mangual
TOP 100 Swiss Startup Award
The TOP 100 Swiss Startup Ranking features the 100 most promising startups that are not older than five years and are selected by a jury of early-stage investors.
Venture Leaders Life Sciences
The venture leaders - the members of the Swiss national startup team- have a clear-cut goal. They envision themselves as global players and want to take the first step to their global expansion. The ten-day business development program is specifically structured to help them achieve this goal.
TOLREMO therapeutics AG
Development of resistance-breaking cancer therapies
Website:
www.tolremo.com
Headquarter:
Basel
Foundation Date:
March 2017
Technology:
- Biotech
Sectors:
- Biotech
- Cancer
- Drug development platforms
- Drug discovery
- Screening
- Small molecule drugs
Support received
